The multifactorial challenges
like patent expiry of several blockbusters, increasing pressure
from the Government
and health insurance bodies
on prices, increased R & D expenses with ever narrowing pipeline
of new products , faced by the pharmaceutical and health care industry
today is forcing the industry to focus on reducing the cost and the
time taken by the drug discovery value chain through close collaboration
with biotechnological and smaller R & D service companies.
With cost effective and
skilled manpower in abundance, strong knowledge in chemistry
and life sciences
coupled with power in
computing, India is proving to be an internationally accepted partner
in manufacturing and exporting active pharmaceutical ingredients,
drug intermediates, and biologics as well as in biotechnological
R&D. Partnership between European and Indian Pharmaceutical companies
can accelerate clinical research and reduce overall costs and bottlenecks
in clinical data management.
Besides the rapid pace of technological growth, emerging markets and market trends are making cross-border partnerships imperative, also for the white and green sectors of biotechnology.
ELGA Biotech has strong
roots both in India and Europe with wide ranging knowledge and
expertise in business management, business development,
strategic innovation and intellectual property management, financing, R&D and marketing. Let ELGA Biotech
serve you by taking care of all your needs in your plans of cross-border
partnership for a profitable future. |
